Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimizing T-cell receptor avidity with somatic hypermutation.
Bassan D, Gozlan YM, Sharbi-Yunger A, Tzehoval E, Eisenbach L. Bassan D, et al. Among authors: sharbi yunger a. Int J Cancer. 2019 Nov 15;145(10):2816-2826. doi: 10.1002/ijc.32612. Epub 2019 Aug 24. Int J Cancer. 2019. PMID: 31381134
Avidity optimization of a MAGE-A1-specific TCR with somatic hypermutation.
Bassan D, Gozlan YM, Sharbi-Yunger A, Tzehoval E, Greenstein E, Bitan L, Friedman N, Eisenbach L. Bassan D, et al. Among authors: sharbi yunger a. Eur J Immunol. 2021 Jun;51(6):1505-1518. doi: 10.1002/eji.202049007. Epub 2021 May 5. Eur J Immunol. 2021. PMID: 33835499 Free PMC article.
Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models.
Grees M, Sharbi-Yunger A, Evangelou C, Baumann D, Cafri G, Tzehoval E, Eichmüller SB, Offringa R, Utikal J, Eisenbach L, Umansky V. Grees M, et al. Among authors: sharbi yunger a. Oncoimmunology. 2018 Mar 26;7(7):e1445457. doi: 10.1080/2162402X.2018.1445457. eCollection 2018. Oncoimmunology. 2018. PMID: 29900058 Free PMC article.
HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity.
Bassan D, Weinberger L, Yi J, Kim T, Weist MR, Adams GB, Foord O, Chaim N, Tabak S, Bujanover N, Lopesco Y, Vucci K, Schnair C, Levy-Knafo L, Kendall RL, Calzone FJ, Sharbi-Yunger A. Bassan D, et al. Among authors: sharbi yunger a. J Immunother Cancer. 2023 Dec 14;11(12):e007426. doi: 10.1136/jitc-2023-007426. J Immunother Cancer. 2023. PMID: 38097342 Free PMC article.